Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance

Table 3 Reversal of chemoresistance

Target	Inhibitors	Cancers	Resistant drugs or sensitized drugs	References
BRD4	JQ1	Ovarian cancer	Cisplatin	[45, 119]
		NSCLC	TRAIL, cisplatin	[142]
		Breast cancer	Salinomycin	[121]
		Breast cancer	AKTi	[170]
		Melanoma	Vemurafenib	[171]
		PDAC	5-FU	[176]
	I-BET151	MCL	Ibrutinib, lenalidomide	[140]
	I-BET151	TNBC	Trametinib	[194]
	I-BET762	NSCLC	TRAIL, cisplatin	[142]
	OTX-015	NSCLC	TRAIL, cisplatin	[142]
	SR2211	Pancreatic adenocarcinoma	Gemcitabine	[117]
	ARV-771	MCL	Ibrutinib, venetoclax, palbociclib	[177]
	MS417	Breast cancer	AKTi	[170]
H3K27ac	TSA	Glioblastoma	Temozolomide	[183]
CDK7	THZ1	B cell lymphoma	ABT-199	[191]
CDK12	THZ531	Anaplastic thyroid carcinoma	Doxorubicin	[192]

NSCLC non-small cell lung cancer, PDAC pancreatic ductal adenocarcinoma, MCL mantle cell lymphoma, TNBC triple-negative breast cancer, AKTi AKT inhibitor, TRAIL tumor necrosis factor-related apoptosis-inducing ligand

ISSN: 1756-9966